6H-Oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
申请人:Schiemann Kai
公开号:US20080051394A1
公开(公告)日:2008-02-28
Compounds of the formula I
in which R
1
, R
2
, R
3
and R
4
are as defined in Claim
1,
are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.
公式I中的化合物,其中R1、R2、R3和R4如权利要求1所定义,是尼古丁乙酰胆碱受体和/或血清素配体的配体,适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症,特别是阿尔茨海默病和Lewy小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化、亨廷顿病、抽动症、学习和记忆障碍、暴食症、厌食症或其他进食障碍、强迫行为、经前综合征、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中毒化合物引起的中风或脑损伤,并用于治疗其特征为循环血清素过多或存在血清素活性亢进的疾病。